May 7 Quick Takes: Gaboxadol meets in Phase II for Fragile X; plus Innovent, Lilly, Tetraphase and more

Ovid’s gaboxadol meets in Phase II for Fragile X
Ovid Therapeutics Inc. (NASDAQ:OVID) said gaboxadol (OV101) met its primary safety endpoint and reduced behavioral and functional symptoms in the Phase II ROCKET trial to treat males ages 13 to 22 with Fragile X syndrome. The selective extrasynaptic agonist of GABRD has Orphan Drug and Fast Track designation for the indication.

Innovent, Lilly combo meets in Phase III for NSCLC
Innovent Biologics Inc. (HKEX:1801) and Eli Lilly and Co. (NYSE:LLY) said the Phase III ORIENT-12 trial showed PD-1 inhibitor Tyvyt sintilimab and Gemzar gemcitabine plus platinum chemotherapy met the primary endpoint of improving progression-free survival vs. Gemzar and chemotherapy alone to treat first-line advanced or metastatic squamous non-small cell lung cancer...